AVNS AVANOS MEDICAL, INC.

Price Chart

Executive Summary

Avanos Medical enters a definitive agreement to be acquired by American Industrial Partners (AIP) for $25.00 per share in cash, representing a 72% premium to the last unaffected closing price of $14.53. The all-cash deal values Avanos at approximately $1.17 billion in equity value, with total required funds of ~$1.42 billion including debt repayment and equity award settlements. The board unanimously recommends approval; a special stockholder vote is set for July 22, 2026.

Key Financial Metrics

Actionable Insight

Key Facts

• Merger consideration: $25.00 per share in cash, no stock component or CVR
• Premium of ~72% based on $14.53 closing price on April 13, 2026 (last pre-announcement trading day)
• Equity commitment of $1.4 billion from AIP Fund; no financing condition for Parent
• Total required funds for the deal: ~$1.42 billion including debt repayment and equity award settlements
• Board of Directors unanimous recommendation FOR the merger proposal
• Special meeting scheduled for July 22, 2026; record date June 18, 2026
• J.P. Morgan issued fairness opinion that $25.00 per share is fair from a financial point of view
• Approval requires majority of outstanding shares; abstentions and failures to vote count as AGAINST
• Appraisal rights available under DGCL Section 262 for dissenting stockholders
• Termination fee payable by Avanos: $37.5 million in certain circumstances
• Closing expected in second half of 2026, subject to regulatory approvals (HSR, multiple foreign jurisdictions) and stockholder vote
• Directors and executive officers holding ~0.35% of outstanding shares expected to vote in favor

Financial Impact

$25.00 per share in cash, ~72% premium to unaffected price of $14.53, total equity value ~$1.17B based on 46.85M shares outstanding

Risk Factors

• Regulatory delays or failure to obtain Required Regulatory Approvals (multiple foreign jurisdictions)
• Antitrust challenge in any of the six Required Government Authority countries
• Stockholder vote failure: abstentions and non-votes count as AGAINST, requiring majority of all outstanding shares
• Material Adverse Effect clause could allow termination if Avanos business deteriorates significantly
• Litigation risk: though none filed as of proxy date, deal-related lawsuits are common
• Termination fee of $37.5M is not large relative to deal value (~3.2%) but could deter competing bidders

Market Snapshot

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

US Market Status